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The PARTNER 3 Bicuspid Registry
for Transcatheter Aortic Valve
Replacement in Low-Surgical-Risk
Patients
Mathew R. Williams, MD,a,* Hasan Jilaihawi, MD,a,* Raj Makkar, MD,b William W. O’Neill, MD,c Robert Guyton, MD,d
S. Chris Malaisrie, MD,e David L. Brown, MD,f Philipp Blanke, MD,g Jonathon A. Leipsic, MD,g
Philippe Pibarot, DVM, PHD,h Rebecca T. Hahn, MD,i,j Martin B. Leon, MD,i,j David J. Cohen, MD,j,k
Jeroen J. Bax, MD, PHD,l Susheel K. Kodali, MD,i Michael J. Mack, MD,f Michael Lu, PHD,m John G. Webb, MDg

ABSTRACT
OBJECTIVES The study compared 1-year outcomes between transcatheter aortic valve replacement (TAVR)
patients with bicuspid aortic valve (BAV) morphology and clinically similar patients having tricuspid aortic valve (TAV)
morphology.
BACKGROUND There are limited prospective data on TAVR using the SAPIEN 3 device in low-surgical-risk
patients with severe, symptomatic aortic stenosis and bicuspid anatomy.
METHODS Low-risk, severe aortic stenosis patients with BAV were candidates for the PARTNER 3 (Placement
of Aortic Transcatheter Valves 3) (P3) bicuspid registry or the P3 bicuspid continued access protocol. Patients treated in
these registries were pooled and propensity score matched to TAV patients from the P3 randomized TAVR trial. Outcomes
were compared between groups. The primary endpoint was the 1-year composite rate of death, stroke, and cardiovascular
rehospitalization.
RESULTS Of 320 total submitted BAV patients, 169 (53%) were treated, and most were Sievers type 1.
The remaining 151 patients were excluded caused by anatomic or clinical criteria. Propensity score matching with the
P3 TAVR cohort (496 patients) yielded 148 pairs. There were no differences in baseline clinical characteristics;
however, BAV patients had larger annuli and they experienced longer procedure duration. There was no difference in
the primary endpoint between BAV and TAV (10.9% vs 10.2%; P ¼ 0.80) or in the rates of the individual components (death: 0.7% vs 1.4%; P ¼ 0.58; stroke: 2.1% vs 2.0%; P ¼ 0.99; cardiovascular rehospitalization: 9.6% vs
9.5%; P ¼ 0.96).
CONCLUSIONS Among highly select bicuspid aortic stenosis low-surgical-risk patients without extensive raphe or
subannular calciﬁcation, TAVR with the SAPIEN 3 valve demonstrated similar outcomes to a matched cohort of
patients with tricuspid aortic stenosis. (J Am Coll Cardiol Intv 2022;15:523–532) © 2022 by the American College of
Cardiology Foundation.
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ABBREVIATIONS
AND ACRONYMS
AVA = aortic valve area
BAV = bicuspid aortic valve
CAP = continued access

B

icuspid aortic valve (BAV) disease is

the multidetector computed tomography core labo-

the most common congenital cardiac

ratory, could be enrolled under the P3 CAP. Oversight

abnormality, affecting approximately

of the P3 CAP was provided by The Society of Thoracic

1% of the general population.1 It most

Surgeons/American College of Cardiology Trans-

commonly causes aortic stenosis, accounting

catheter Valve Registry.

for up to one-half of patients requiring surgi-

protocol

Key

inclusion

criteria

for

TAV

and

BAV

cal aortic valve replacement (SAVR). 2 Trans-

patients were identical, including severe calciﬁc

catheter aortic valve replacement (TAVR)

aortic stenosis with aortic valve area (AVA) #1.0 cm 2

overall summary

has been shown to be a safe and effective

or AVA index #0.6 cm 2/m 2 with jet velocity $4.0 m/s

KM = Kaplan-Meier

therapy for patients with aortic stenosis at

or mean gradient $40 mm Hg, with symptoms either

NYHA = New York Heart

low

because

reported or elicited on exercise testing. Low surgical

Association

tricuspid aortic valve (TAV) morphology was

risk was deﬁned by a Society of Thoracic Surgeons

P3 = PARTNER 3 trial

an inclusion criterion for these trials, this

Predicted Risk of Mortality (STS PROM) score of <4%,

PVR = paravalvular

foundational evidence can only be applied

or by judgment of the local heart team and national

regurgitation

to TAV patients. While national registries

case review committee. Anatomic exclusion criteria

SAVR = surgical aortic valve

have shown some promise for TAVR in BAV

included severe left ventricular outﬂow tract or raphe

replacement

anatomy in intermediate- and high-surgical-

calciﬁcation, aortic annulus diameter <16 mm or

STS PROM = The Society of

risk patients, the data are often site reported

>28 mm, and ascending aorta diameter >4 cm.

with limited oversight of hemodynamic or

Comprehensive inclusion and exclusion criteria have

clinical outcomes. 4,5 Moreover, the data in

been previously reported.3

KCCQ-OS = Kansas City
Cardiomyopathy Questionnaire

Thoracic Surgeons Predicted
Risk of Mortality

TAV = tricuspid aortic valve
TAVR = transcatheter aortic
valve replacement

surgical

risk.3

However,

patients at low surgical risk remain very

The Institutional Review Board at each partici-

limited, 6 with no available randomized data

pating site approved the protocols, and all patients

to date comparing TAVR with SAVR in BAV

provided written informed consent.

anatomy. The objectives of this study were to: 1) pro-

ENDPOINT. The primary endpoint for this analysis

spectively study the 1-year safety and efﬁcacy out-

was the composite of all-cause mortality, all stroke,

comes of TAVR with the SAPIEN 3 valve in low-

and cardiovascular rehospitalization (valve related or

surgical-risk patients with severe BAV stenosis: and

procedure related and including heart failure) at 1

2) employ propensity score matching to compare these

year after valve implantation. An independent clin-

data to that of a clinically similar cohort of TAV pa-

ical events committee adjudicated the components of

tients treated in the low-risk PARTNER 3 (Placement

the primary endpoint for patients enrolled in P3 and

of Aortic Transcatheter Valve 3) (P3) trial. 3 This analysis

incorporated

high-quality

prospective

data

the P3 BAV registry. Clinical data for patients studied
under the P3 CAP were adjudicated by an indepen-

collected in a trial with independent oversight of clin-

dent

ical outcomes and core laboratory evaluation of base-

included

line anatomy and echocardiographic outcomes.

symptom status classiﬁed according to the New York

SEE PAGE 533
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Secondary
permanent

(NYHA),

and

endpoints
pacemaker,

quality

of

life

measured by the Kansas City Cardiomyopathy Ques-

METHODS
STUDY DESIGN AND PARTICIPANTS. This analysis

used patients from the P3 trial, patients from the P3
BAV registry, and those studied under the P3 bicuspid
continued access protocol (CAP). Prior to enrollment,
patients were screened for eligibility by a multidisciplinary heart team and national case review board.
Multidetector computed tomography analyzed by the
study core laboratory was used to determine anatomic
eligibility for the trial. Patients with TAV morphology
were considered for the randomized P3 trial, whereas
those with BAV morphology were considered for the

tionnaire overall summary (KCCQ-OS) score.
ECHOCARDIOGRAPHY. Post-TAVR echocardiograms

were collected to assess hemodynamic function of
the implanted valve at 30 days and 1 year. A core laboratory read echo data for patients included in P3 and
the P3 BAV registry. Paravalvular regurgitation (PVR)
was graded as none or trace, mild, mild to moderate,
moderate, moderate to severe, or severe and then reported here as none or trace, mild, and $moderate.
The P3 CAP PVR data were site reported as none
or trace, mild, and $moderate. Core laboratory
results were not statistically compared with sitereported data.

single-arm P3 BAV registry. Following completion of

STATISTICAL METHODS. Patients in the P3 BAV reg-

P3 enrollment, patients meeting study inclusion and

istry and the P3 CAP were pooled to form one BAV

exclusion criteria, including conﬁrmation of BAV by

group. To identify clinically comparable BAV and TAV
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F I G U R E 1 Study Workﬂow

This ﬂow chart demonstrates the number of patients that were submitted for screening from each source (PARTNER 3 [Placement of Aortic Transcatheter Valve 3] [P3]
bicuspid registry, P3 continued access protocol [CAP], and P3 transcatheter aortic valve replacement (TAVR) patients with tricuspid anatomy), the number that were
excluded for anatomical or clinical reasons, and the remaining number treated and available for propensity score matching. Finally, the propensity-matched analysis
cohorts are shown. CT ¼ computed tomography; inc/exc ¼ inclusion/exclusion; PI ¼ principal investigator; proc ¼ procedure; SAVR ¼ surgical aortic valve
replacement.

cohorts, a 1:1 propensity score–matching analysis was

30 days and 1 year are presented as Kaplan-Meier (KM)

performed. For each cohort, a propensity score for

rates. Additional clinical outcomes are reported as KM

being in the BAV group was calculated using a logistic

or incidence rates. Continuous variables are presented

regression model. The following baseline variables

as mean  SD. Baseline characteristics and echocar-

were used as covariates: age, sex, New York Heart

diographic measurements were compared using a

Association (NYHA) functional class, body mass in-

2-sample Student’s t-test. The postprocedural KCCQ-

dex, STS PROM score, diabetes mellitus, peripheral

OS scores were compared using analysis of covariance.

vascular disease, carotid disease, hypertension, renal

Continuous variables associated with procedural out-

disease, atrial ﬁbrillation, prior cerebrovascular acci-

comes are presented as median (IQR) and were

dent, prior percutaneous coronary intervention,

compared using the Wilcoxon rank sum test. Cate-

aortic valve mean gradient, effective oriﬁce area,

gorical variables were compared using Fisher exact

mitral insufﬁciency, and KCCQ-OS score. Where

test. Time-to-event variables presented with KM es-

necessary, missing baseline covariates were imputed

timates were compared using the log-rank test.

using multiple imputation according to the fully
conditional speciﬁcation method. The matching was

RESULTS

performed using a greedy matching algorithm with a
The study workﬂow is presented in Figure 1. Patients

speciﬁed caliper distance of 0.20.
Analyses of clinical outcomes, NYHA functional

from 28 centers in the United States were included in

class, and KCCQ-OS score were performed on both the

this study (Supplemental Table 1). Of 133 patients

propensity

pop-

screened for the P3 BAV registry, 62 (46.6%) were

ulations. Results for the composite primary endpoint

excluded, yielding 71 treated patients. Of 187 patients

and its individual components (all-cause mortality, all

screened for the P3 CAP, 89 were excluded, yielding

stroke,

98 treated patients. The total number of treated

and

score–matched

cardiovascular

and

unmatched

rehospitalization)

at
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7.4% [IQR: 1.1% to 13.5%]; P < 0.01) (Supplemental

T A B L E 1 Anatomical Exclusions

Table 3). The BAV procedures were on average 9 miP3 BAV Registry
(n ¼ 43)

P3 CAP
(n ¼ 56)

3 (7.0)

24 (42.0)

9 (20.9)

13 (23.0)

Severe LVOT calciﬁcation

1 (2.3)

4 (7.0)

Risk of coronary obstruction

1 (2.3)

3 (5.0)

Severe raphe calciﬁcation and severe LVOT
calciﬁcation

1 (2.3)

2 (4.0)

Unsuitable annulus size

1 (2.3)

1 (2.0)

Reason for Exclusion

Severe raphe calciﬁcation
Ascending aorta diameter >4 cm

nutes longer with longer ﬂuoroscopy times. Conscious
sedation was used in two-thirds of the procedures with
no difference between BAV and TAV groups. There was
only 1 conversion to SAVR (this was in the TAV group).
Outcomes of the unmatched populations are
shown (Supplemental Table 4). In the BAV group,
there was 100% procedure success versus 99.6% in
the TAV group. There was 1 case of coronary
obstruction

requiring

intervention

in

the

BAV

Very extreme leaﬂet/annular calciﬁcation in a
type 2 bicuspid

1 (2.0)

Ascending aorta diameter >4 cm and severe LVOT
calciﬁcation

4 (7.0)

rupture or aortic dissection or in-hospital deaths.

Ascending aorta diameter >4 cm and severe raphe
calciﬁcation

2 (4.0)

for propensity score matching against 496 eligible

Ascending aorta diameter >4 cm and severe raphe
calciﬁcation and severe LVOT calciﬁcation

1 (2.0)

Inadequate iliofemoral vessel characteristics

1 (2.0)

Signiﬁcant abdominal or thoracic disease
Tricuspid aortic valve

group (under the P3 CAP). There were no cases of root
The combined BAV group had 169 patients eligible

pairs with no signiﬁcant difference in baseline clinical
characteristics or transvalvular gradients; however,

1 (2.3)

the larger annular area in BAV patients remained

15 (34.9)

signiﬁcant, as did the lesser degree of valvular over-

Unsuitable annulus size and ascending aorta
diameter >4 cm

1 (2.3)

Unsuitable annulus size and risk of coronary
obstruction

1 (2.3)

Unsuitable annulus size and severe raphe calciﬁcation

1 (2.3)

a

TAV patients in P3 (Figure 1). Matching yielded 148

sizing (Tables 2 and 3). The median follow-up time
was 374.5 days (IQR: 366.5-391.0 days) in the BAV

Structurally abnormal LVOT and annulus

1 (2.3)

Aortic stenosis not calciﬁc

2 (4.7)

Aortic stenosis not calciﬁc and ascending aorta
diameter >4 cm

1 (2.3)

Severe raphe calciﬁcation and ascending aorta
diameter >4 cm

2 (4.7)

Small sinus of Valsalva and/or sinotubular junction

2 (4.7)

group and 380.5 days (IQR: 370.5-496.0 days) in the
TAV group. At 30 days, there were no signiﬁcant
differences in death (0% vs 0%), stroke (1.4% vs
1.4%), rehospitalization (5.4% vs 4.1%), or their
composite (6.8% vs 4.7%) between BAV and TAV
groups. Similarly, at 1 year, rates of death (0.7% vs
1.4%), stroke (2.1% vs 2.0%), rehospitalization (9.6%
vs 9.5%), and the composite primary endpoint (10.9%

Values are n (%). aExclusion for this patient was reported by the site.
BAV ¼ bicuspid aortic valve; CAP ¼ continued access protocol; LVOT ¼ left ventricular outﬂow tract;
P3 ¼ PARTNER 3 (Placement of Aortic Transcatheter Valves 3) trial.

vs 10.2%) were not different between groups (Table 4,
Central Illustration). The frequency of permanent
pacemaker implantation at 30 days was similar (6.1%
vs 6.8%). The NYHA functional class and KCCQ-OS
scores were also similar between the BAV and TAV
groups at both time points (Figure 2).
Echocardiographic ﬁndings are shown for un-

bicuspid patients available for analysis was 169.

matched patients from P3 TAV, P3 BAV registry, and

Bicuspid morphology was Sievers type 1 in 145

P3 CAP (Figure 3). At 30 days, moderate or greater PVR

(85.8%) patients, 23 (13.6%) patients were type 0, and

was seen in 0.8% of P3 TAV patients, 1.4% of P3 BAV

1 (0.6%) patient was type 2. The reasons for anatom-

registry patients, and 2.3% of the P3 CAP patients;

ical exclusion are listed in Table 1.

mean aortic valve gradient was 12.8  0.2 mm Hg in

Prior to matching, the combined group of 169 BAV

P3 TAV, 14.0  0.6 mm Hg in the P3 BAV registry, and

patients was younger, had smaller body mass index,

12.5  0.53 mm Hg in the P3 CAP (Figure 3). The

had lower STS PROM scores, and had a larger propor-

ﬁndings were similar at 1 year.

tion of females than the TAV group. The BAV group
also had less hypertension, atrial ﬁbrillation, diabetes,

DISCUSSION

renal insufﬁciency, prior percutaneous coronary
intervention, and diabetes, and it showed higher

This prospective evaluation of contemporary balloon-

transvalvular gradient and lower effective oriﬁce area

expandable TAVR in BAV aortic stenosis, in patients

at baseline (Supplemental Table 2). There was a trend

at low surgical risk, showed rates of death, stroke,

to larger annuli but with less aggressive oversizing

rehospitalization, and new pacemaker implantation

employed (BAV 4.4% [IQR: 0.7% to 11.3%] vs TAV

that were similar to those in a propensity-matched
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T A B L E 2 Baseline Characteristics for Matched Subjects

Age, y
Male

Bicuspid
(n ¼ 148)

Tricuspid
(n ¼ 148)

71.0 (68.075.0) (148)

72.0 (68.075.0) (148)

0.76

89/148 (60.1)

0.81

86/148 (58.1)

Body mass index, kg/m2
Hypertension
Prior stroke

T A B L E 3 Procedural Outcomes in Matched Subjects

28.0 (25.230.8) (148)

27.6 (25.1-31.3) 0.98
(148)

109/146 (74.7)

112/148 (75.7)

0.89

4/148 (2.7)

6/148 (4.1)

0.75

Carotid disease

12/124 (9.7)

14/146 (9.6)

>0.99

History of atrial ﬁbrillation

7/148 (4.7)

2/148 (1.4)

0.17

Diabetes mellitus

26/147 (17.7)

27/148 (18.2)

>0.99

Renal insufﬁciency

8/148 (5.4)

9/148 (6.1)

>0.99

Peripheral vascular disease

4/148 (2.7)

5/147 (3.4)

0.75

Prior PCI

16/148 (10.8)

17/147 (11.6)

0.86

NYHA functional class III/IV

44/148 (29.7)

39/148 (26.4)

0.60

Mitral regurgitation
$moderate

4/113 (3.5)

4/146 (2.7)

0.73

Tricuspid regurgitation
$moderate

3/143 (2.1)

1/144 (0.7)

0.37

Mean gradient, mm Hg

49.0 (42.058.0) (147)

50.1 (40.260.6) (145)

0.57

0.7 (0.6-0.8)
(140)

0.7 (0.6-0.8)
(136)

0.57

72.7 (55.5-83.6)
(148)

72.9 (53.985.9) (147)

0.54

1.4 (1.0-1.9)
(148)

1.5 (1.2-1.8)
(148)

0.67

AV area, cm

2

KCCQ-OS score
STS PROM score, %

Bicuspid
(n ¼ 148)

Tricuspid
(n ¼ 148)

Procedure duration, min

64.0 (46.0 to
89.5)

50.0 (36.0 to
65.0)

<0.01

Fluoroscopy time, min

13.3 (10.0 to
19.8)

12.0 (9.0 to
16.0)

<0.01

486.0 (406.2 to
541.6) (147)

457.1 (390.3 to
516.3) (144)

0.01

2/148 (1.4)

5/148 (3.4)

23 mm

47/148 (31.8)

56/148 (37.8)

26 mm

68/148 (45.9)

61/148 (41.2)

29 mm

31/148 (20.9)

26/148 (17.6)

49/148 (33.1)

61/148 (41.2)

99/148 (66.9)

87/148 (58.8)

P Value

Annulus area, mm2
Valve size

0.42

20 mm

Valve size grouped

0.19

20 or 23 mm
26 or 29 mm
Annular oversizing, %

4.4 (-0.5 to 11.6) 7.6 (1.1 to 13.8)
(147)
(144)

Type of anesthesia used

Values median (IQR) (n) or n/n (%). The t test was used to compare continuous
variables and Fisher exact test was used for categorical ones.

P Value

0.02
0.54

General

45/148 (30.4)

55/148 (37.2)

Conscious sedation

102/148 (68.9)

92/148 (62.2)

1/148 (0.7)

1/148 (0.7)

Procedure aborted

0/148 (0.0)

0/148 (0.0)

NA

Conversion to SAVR

0/148 (0.0)

1/148 (0.7)

>0.99

Conscious sedation to
general

Procedure success

148/148 (100.0)

147/148 (99.3) >0.99

Values median (IQR) (n) or n/n (%). The Wilcoxon rank sum test was used to
compare groups for procedure time and ﬂuoroscopy time. The t test was used for
comparison of groups for annular area. Fisher’s exact test was used to compare
groups with categorical variables.
NA ¼ not applicable; SAVR ¼ surgical aortic valve replacement.

AV ¼ aortic valve; KCCQ-OS ¼ Kansas City Cardiomyopathy Questionnaire
overall summary; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention; STS PROM ¼ The Society of Thoracic Surgeons Predicted Risk
of Mortality.

combination, which they observed in a quarter of
patients undergoing TAVR, may be regarded as high
cohort of patients with TAV aortic stenosis. Moreover,

anatomical, or “high estimated TAVR risk,” with the

important echocardiographic outcomes such as para-

presence of either severe valve or severe raphe

valvular regurgitation and transvalvular gradients
were also similar in the populations studied.
CASE SELECTION AND ANATOMICAL RISK OF TAVR

T A B L E 4 Clinical Outcomes in Matched Subjects

IN BAV AORTIC STENOSIS. Unlike TAV, BAV anat-

Time
Point

Bicuspid
(n ¼ 148)

Tricuspid
(n ¼ 148)

P Value

Death, stroke, or
rehospitalization

30 d
1y

10 (6.8)
16 (10.9)

7 (4.7)
15 (10.2)

0.44
0.80

Death

30 d
1y

0 (0.0)
1 (0.7)

0 (0.0)
2 (1.4)

NA
0.58

Rehospitalization

30 d
1y

8 (5.4)
14 (9.6)

6 (4.1)
14 (9.5)

0.58
0.96

Stroke

30 d
1y

2 (1.4)
3 (2.1)

2 (1.4)
3 (2.0)

0.99
0.99

New permanent pacemaker

30 d
1y

9 (6.1)
10 (6.8)

10 (6.8)
11 (7.4)

0.81
0.82

omy is highly heterogeneous. Patients exhibit variable degrees of valve calciﬁcation as well as raphe
calciﬁcation, when a raphe is present. Hence, one
must be careful not to extrapolate the ﬁndings
observed in this study to the entire BAV low-surgicalrisk population.
A new imaging-based anatomical framework for
BAV risk assessment has been recently proposed, in
which patients with a combination of severe valvular
and severe raphe calciﬁcation were identiﬁed at
highest risk for adverse outcomes including root
injury and paravalvular regurgitation. 2 Based on
these data of Yoon et al,

2

Values are n (%). The P values were determined from the log-rank test.
NA ¼ not applicable.

the presence of this
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C E NT R AL IL L U STR AT IO N Time-to Event Curves for Propensity-Matched Tricuspid and Bicuspid Patients
Through 1 Year
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Williams, M.R. et al. J Am Coll Cardiol Intv. 2022;15(5):523–532.

Kaplan-Meier rates are shown for (A) death, (B) stroke, (C) cardiovascular rehospitalization, and (D) the composite primary endpoint (death, stroke, or rehospitalization
[Rehosp]) through 1 year in propensity score–matched bicuspid and tricuspid groups. The P values were determined from the log-rank test. There were no signiﬁcant
differences between groups for any outcome. TAVR ¼ transcatheter aortic valve replacement.

calcium indicating “intermediate estimated TAVR

present study must be placed in this context of a large

risk.” Indeed, the presence of subvalvular (also

cohort of BAV patients excluded based on these

known as left ventricular outﬂow tract) calcium may

anatomical criteria. This is a testament to appropriate

also be considered an indicator of “high estimated

case selection for the study but raises a caveat on the

TAVR risk” for patients with both BAV and TAV. Such

extrapolation of its ﬁndings to the entire BAV

patients with severe left ventricular outﬂow tract

population.

calcium or severe raphe calcium were, per protocol,

In contrast to surgical risk, which is clearly quan-

excluded from the present study. Although most

tiﬁable by clinical parameters in the STS PROM score,

anatomical exclusions were for tricuspid anatomy in

quantiﬁcation

P3 BAV registry, severe raphe calciﬁcation accounted

anatomically driven

for 42% of anatomical exclusions from the P3 BAV

concept for future research; in the absence of such

CAP (Table 1). Thus, the favorable outcomes of the

clarity, undoubtedly when evaluating low-surgical-

of

TAVR
and

risk

is

remains

predominantly
an
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F I G U R E 2 Health and Symptom Status Through 1 Year

(A) The overall summary score for the Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline, 30 days, and 1 year is shown. The scale
ranges from 0 to 100, with an increasing number indicating better health. Group means at each time point were compared using analysis of
covariance. Bicuspid patients had a signiﬁcantly better quality of life relative to tricuspid patients at 30 days, but this difference disappeared at
1 year. Both groups had a clinically meaningful improvement relative to baseline. Error bars represent 95% CIs. (B) The percentage of
patients in New York Heart Association functional class III or IV at baseline, 30 days, and 1 year is presented. The P values were calculated
from Fisher exact test. Almost no patients remained with New York Heart Association functional class III or IV symptoms following treatment.

risk BAV patients, the heart team should carefully

OTHER ANATOMICAL CONSIDERATIONS IN THE BAV

consider the putative, currently qualitative, “esti-

POPULATION. Even in the absence of a raphe, pat-

mated TAVR risk” and appropriately direct patients

terns of calciﬁcation exist that could signiﬁcantly

with elevated estimated TAVR risk to SAVR. There is

impact device expansion. For instance, calciﬁcation

considerable scope in the future for greater precision

may be extremely asymmetric and can also be

in this anatomical-based selection, including a po-

circumferential or near circumferential, regardless of

tential

Sievers subtype. Such patterns may also present

application

of

artiﬁcial

intelligence

computer-derived predictive algorithms. 7,8

and

elevated “estimated TAVR risk.”
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F I G U R E 3 Hemodynamics Through 1 Year

The available echocardiography data are presented for the bicuspid and tricuspid patients without propensity score matching. Data for
patients in the P3 CAP were provided by the sites, whereas data from P3 TAVR and the P3 bicuspid registry were analyzed by a core laboratory. No statistical comparisons were performed between groups. (A) The line chart representation of mean gradient (MG) (solid lines) and
effective oriﬁce area (EOA) (dotted lines) at baseline, 30 days, and 1 year demonstrates that treatment relieved ﬂow obstruction across the
aortic valve in bicuspid and tricuspid patients. (B) This stacked bar chart shows that most patients had no paravalvular regurgitation at
30 days and 1 year. NA ¼ not applicable; other abbreviations as in Figure 1.
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The presence of aortopathy is important in the lowsurgical-risk BAV population, as it presents a disease

methods, tables, and ﬁgures, and provided editing
assistance.

state whose only current effective therapy is open
surgery. The presented study erred on the side of
caution in excluding patients with an ascending aorta
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PERSPECTIVES
WHAT IS KNOWN? TAVR is a safe and effective therapy

valve can produce early clinical and echocardiographic

in select high-risk aortic stenosis patients with BAV

outcomes that are similar to those achieved in patients

morphology.

with TAV morphology.

WHAT IS NEW? Among highly select low-surgical-risk

WHAT IS NEXT? Long-term assessment of structural

patients with BAV aortic stenosis with no severe raphe

valve deterioration in low-risk bicuspid patients is

calciﬁcation or aorta dilation, TAVR with the SAPIEN 3

needed.
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